Affordable Access

deepdyve-link
Publisher Website

Lipid Emulsion Therapies and Type 1 Hypersensitivity Reactions: Risk Assessment and Management.

Authors
  • Franz, Nicholas1
  • Pleva, Melissa1
  • Nordbeck, Sarah1
  • 1 Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, Michigan, USA.
Type
Published Article
Journal
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
Publication Date
Apr 01, 2021
Volume
36
Issue
2
Pages
398–405
Identifiers
DOI: 10.1002/ncp.10443
PMID: 31769112
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Over the past decades, awareness and attention given to food allergies has extended further into the realm of pharmacotherapy. Despite the presence of similar ingredients, different intravenous lipid emulsion (ILE)-based medication products have a wide variety of warnings and contraindications for patients with food allergies. Only limited literature is available to guide clinicians in making appropriate medication therapy adjustments to reduce the risk of hypersensitivity reactions in atopic patient populations. Therefore, the authors sought to develop a comprehensive review of potential risk factors or approaches for management of patients with atopic history and need for ILE therapy. Through thorough review of available literature published worldwide, a description of potential contraindications, risk factors, and evaluation methods is presented. Although the current state of knowledge remains relatively poor, this review aims to provide clinicians a better understanding of which risk factors related to the development of hypersensitivity reactions are relevant to lipid emulsion products and how to best manage patients who may be at risk for severe reaction based on their history. Evaluating personal atopic history is essential to the development of an appropriate risk classification system and approaching an individual's therapeutic options. By applying this assessment to local populations, providers should be able to develop an institutional guideline for screening and minimizing risk of substantial hypersensitivity reactions. Finally, a brief review of methods for managing type 1 hypersensitivity reactions is provided in the event that a breakthrough reaction does occur. © 2019 American Society for Parenteral and Enteral Nutrition.

Report this publication

Statistics

Seen <100 times